Eevia Health Oyj (NGM:EEVIA) First Quarter 2024 Results
Key Financial Results
- Revenue: €421.0k (down 75% from 1Q 2023).
- Net loss: €487.0k (down from €17.0k profit in 1Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Eevia Health Oyj shares are down 64% from a week ago.
Risk Analysis
You should always think about risks. Case in point, we've spotted 4 warning signs for Eevia Health Oyj you should be aware of, and 2 of them can't be ignored.
Valuation is complex, but we're here to simplify it.
Discover if Eevia Health Oyj might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NGM:EEVIA
Eevia Health Oyj
Produces and distributes organic bioactive plant extracts in Finland and internationally.
Excellent balance sheet slight.